In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar Therapeutics

www.nektar.com

Latest From Nektar Therapeutics

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Nektar Pins Falling Cancer Response Rate On Manufacturing Problem

A post-hoc analysis linked “physical differences” in two lots of Nektar’s drug to lower efficacy when given in combination with Bristol-Myers Squibb’s Opdivo. Nektar’s share price tumbled following the update.

Clinical Trials Manufacturing

Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Inhale Therapeutic Systems Inc.
  • Nektar Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nektar Therapeutics
  • Senior Management
  • Howard W Robin, Pres. & CEO
    Gil M Labrucherie, SVP, CFO
    Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
  • Contact Info
  • Nektar Therapeutics
    Phone: (415) 482-5300
    455 Mission Bay Blvd. S.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register